Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guess the European bank and French governments who sponsor the funding don’t know what Guinness knows ????????
About the Eiffel Energy Transition Fund
Eiffel Energy Transition is a professional investment fund, strictly reserved to institutional investors, with a 10-year lifespan. The Fund responds to the need of the energy transition sector with an original offer, by offering short term debt to developers while they await long term funding for their projects. The Fund is sponsored by the European Investment Bank, the French governmental agency ADEME and leading European institutional investors, and is managed by Eiffel Investment Group.
News out https://finance.yahoo.com/news/alternus-energy-closes-9-75-123000057.html
Alternus Energy Closes $9.75 Million Financing from Leading European Renewable Energy Investment Fund
GlobeNewswireJune 27, 2019, 1:30 PM GMT+1
Reduces Annual Interest Expense as Proceeds to Repay Higher Cost Debt
New York, NY, June 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Alternus Energy Inc. (OTC: ALTN) (the “Company” or “Alternus”), a global renewable energy company, today announced the successful closing of a EUR €8,628,000 ($9,749,640) from Eiffel Energy Transition Fund S.L.P. The funding is being used to refinance a portion of existing higher cost debt that was used to acquire the recent 7.2MW of solar projects in Italy, and will reduce the annual interest costs for these projects once the Eiffel funds are repaid by October 2019.
Vincent Browne, Alternus Energy’s Chief Executive Officer, President and Chairman, commented, “We appreciate the investment and confidence of our financial partner, Eiffel, in sharing our vision. We continue to see opportunities across Europe for us to a acquire solar park assets, operate and manage them under long-term contracts and generate solid cash flows for our company and shareholders.”
Pierre-Antoine Machelon of Eiffel commented, “We are very pleased to have completed this first transaction with Alternus Energy and we look forward to supporting the Company’s growth in the future as Vincent and his team execute on their growth plans.”
A supplemental filing with full details of the transaction has been filed at https://www.otcmarkets.com/stock/ALTN/disclosure
About Alternus Energy Inc.
Alternus Energy, Inc. is a global renewable energy company that owns and operates Utility Scale Solar parks internationally. Each solar park generates clean energy every day that is sold to national power grids under long term, government counterparty, fixed price contracts. The Company currently has operational solar parks in Germany, Italy and Romania with contracts in place to add additional solar parks in the Netherlands. For further information please go to: www.AlternusEnergy.com
About the Eiffel Energy Transition Fund
Eiffel Energy Transition is a professional investment fund, strictly reserved to institutional investors, with a 10-year lifespan. The Fund responds to the need of the energy transition sector with an original offer, by offering short term debt to developers while they await long term funding for their projects. The Fund is sponsored by the European Investment Bank, the French governmental agency ADEME and leading European institutional investors, and is managed by Eiffel Investment Group.
About Eiffel Investment Group
Eiffel Investment Group is a Paris-based asset manager specialized in SME financing. Eiffel Investment Group invests in European companies’ credit, through stock markets, private placements and digital lending platforms. With its subsidiary Alto Invest, an asset manager specialized in private equity investments, the group manages about 1.6 billion euros and proposes an extensive range of financing solutions. The group, which has significant equity, set in place an institutional infrastructure and makes sure that the interests are aligned with the institutional investors, the clients of the funds. Eiffel Investment Group is an independent company, owned by its team alongside IMPALA. Eiffel Investment Group is a renowned specialist of the energy transition. The company is a member of Finance for Tomorrow which contributes to the promotion of a sustainable finance serving a low carbon economy, and manages funds specialized in the financing of the energy transition.
More information on: https://www.eiffel-ig.com
This is getting funnier. He now has proprietary charts ?????? I need to lie down
Here’s my take on it for what it’s worth. No more, no less they all the idiots on here (myself included)
Company will go nasdaq sooner than later . It’s not if but when
The tmo deal will be huge, why? Because tmo don’t waste their time on small deals in small companies
Look at the board enhancements, this is a board comparable to anything on nasdaq
Look at the management, best if the best from big pharma. All leaving to join pred
Look at the increasing revenues with zero debt and they have yet to launch their flagship products
Look at the attorneys, world leaders in this field
The above is all factual
Now let’s look at the rumors
Big investment banks (plural) hanging around
Major news flow and partnerships after uplist
Multiple analysts reports
Low float , now people are going to jump up and down and say huge float, I’m talking about real stocks on the big boards. This is a low floater and when (again not if) the big funds start buying, this will go up hard
Alleged big short (not a fan of short theories)
And the list goes on and on
Go do your homework, find out exactly what they do and be happy because you have a game changer here.
As for the bird man! I’m 100% sure the bird is the smart one
Let’s look at the missteps
Growing revenues
Tmo relationship
New fda trials
New products
Enhancing executive
Enhancing board
Sounds like a disaster.
The missed expectations have nothing to d with the come but down to misguided exuberance of investors. They haven’t missed deadlines and are still on track. Good to see you back, Sri k will be up tomorrow. Always does when you show up
They have no idea as to what they own and I’m glad the little bird boy was selling and telling people to sell today. Better off without the bottom feeders who want instant gratification
Agreed 100% . It’s degrading for the company to have a guy like this hanging around it like a pariah.
I agree, it’s mind boggling that anyone would listen to him. Seriously not well!
My buddy told him it was a 20c stock low float, needed a push for some funding raising (all bogus) and Davis hit him up for 1m shares to be distributed to his ex (who lives with him? Not sure about this) and some Mexican guy. I’ll ask the name later. I didn’t listen as my friend was livid. I didn’t take the opportunity to say “told you so” as he’s a good guy but it was tempting.
The taking parrot uses big board stocks for legitimatcy and then suckers you in to things like kpay, Rafa etc.
If he was as sharp as he thinks he is, he wouldn’t be broke living with his ex!!
Looks like another 70k today picked up by smart trader quietly mopping up stray shares. My screen showing free but I know it’s hard for you to keep up between breaks.
Break time, enjoy the 15 mins and get back to flipping burgers
Agreed though I’m 100% sure the form 10 is completed because I asked the TA! She confirmed it. As for Barry aka the ice parrot. There’s people in Mongolia who know more about this company. He’s been using it to recover his following from 100 bad stocks over the years and has suckered some new people into his little room. He is a know felon with past sec trading issues. It’s like taking home security advice and a proven thief just out of prison! Some people are so naive. If you listen to the guy for secs you will realize he has zero idea what this company even does! All you hear is stem cells and $300 target.
He got lucky, found this below the radar gem but it’s time to grow up and realize this guy is a prize clown but very dangerous
Yes, wanted to see what kind of guy this clown is and he has a big pred position. I told him to read tealeaves as they would tell him more than this guy would. He didn’t listen but tested him out with the “new company “ thing. The response was priceless! Our stock here here and here and I’ve a huge following (he owns up to 20m pred seemingly in his group!) and they would buy what he told them to. Crazy.
But he’s a trading genius who gives his honest opinion !!!??????
You’re 100% right. The bird man is a crook and if your naive enough to believe anything he says then god help you. I’m with you, bought down here. Let’s see where we in a few months, not a few data like the bird boy and his stupid predictions
Hearing that Barry and Kim are selling stock or sold stock and are looking to buy back in hence him telling people stock is going down. Has anyone ever contemplated that the bird is working for the shorts? He obviously had no connection to the company? Is he playing everyone for a fool?
I had a friend call him about a made up company and offer him a lot of stock. He didn’t even care what the company was or what he was doing, he asked for stock to be transferred to his ex wife (Kim I presume?) and some Mexican guy. This guy is not to be trusted
There is none, Davis is an idiot and a pumper. When he’s pumping he’s selling and when he’s negative he’s buying, that’s his MO for 35 years. He hasn’t a clue what’s going on and got lucky years ago by finding this and is trying to make some kind of comeback on the back of it.
The company never gave him stock (I asked ) and he’s just trying to be relevant. There are no shorts paying for promos and nasdaq do things in their time and it will happen soon. How soon is up to nasdaq, not some guy with a bloody parrot on his head! Seriously who takes advice from a guy who has a bird in his head!
No they aren’t!! Where’s the logic!! This is irrelevant from a nasdaq persoectice
I’m going to answer this even though anyone who listens to Davis needs to be taken to a shrink. When he doesn’t know anything his mouth can’t help spue verbal crap. He never know what was going g on so why do you think he does now?
He’s always looking for something to talk about and most of it is mindless
Nope, didn’t even see your reply. I’d imagine I-hub deleted it due it being stupid but I’m only basing that on the rest of your posts
I have reason to be here!! Who else is going to make fun of you!!
There he is, like clockwork, waiting by his little screen waiting for a tick down in $3000 . Instant validation ??????
I think the point he’s making is that the management team is nowhere near these guys. The company executing is the important as shown in today’s news. Guys jumping on bandwagon or guys sound stuff for their own reasons to appear important is unimportant
It was sent to me and I thought it should be shared. Very well structured piece and shows where the company is going. Most (even longs) don’t turkey understand what is happening here
Predictive Technology Group Announces the Presentation of New Data Demonstrating the Genetic Basis of Endometriosis at ESHRE
SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics and novel treatment approaches. The study data was discussed in an oral presentation by Kenneth Ward, M.D. at the 2019 European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Vienna, Austria.
The abstract of the presentation “Excess germline mutations in four genes in unrelated women with surgical endometriosis” is available at https://www.eshre.eu/ESHRE2019/Programme/Searchable#!abstractdetails/0000581010.
“Predictive Laboratories is committed to comprehensive disease management and advancing research into the genetic cause of endometriosis to improve the diagnosis and management of patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group. “Our investment in technology has led to the identification of additional germline DNA changes associated with endometriosis.”
The study was conducted to identify genes in patients with endometriosis versus the general population. Whole exome sequencing was used to identify four genes (ZNF586, LUZP4, POP4 and UNC5CL) with significant gene burden in over 2,500 women with endometriosis, which was significant versus the general population (p<5 x 10-8). The four newly discovered mutated genes are all involved in the regulation of gene expression. Importantly, it was found that one in four women with endometriosis carry a mutation in one of these genes, while the population frequency is only 8%.
“Our research may lead to a better understanding of the pathophysiology of endometriosis,” said Dr. Ward, CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. “Given the pace of innovation for targeted therapy, we are thrilled to present clinically relevant insights that may result in improved treatment of infertility as a result of endometriosis.”
About Endometriosis
Endometriosis occurs when the endometrial tissue that lines the uterus grows outside of the uterus and onto other areas of the body. Symptoms include pelvic pain, heavy periods, pain during sexual intercourse or bowel movements and infertility. Endometriosis affects 1 in 10 women worldwide in the reproductive age group. This prevalence increases to 1 in 3 women with infertility and 1 in 2 women with a normal cycle whose partner has normal sperm.
About ESHRE
The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world's major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.
Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Very well written piece
Predictive Technology Group Inc. (PRED)
Data analytics has the potential to solve some of the greatest challenges facing the world.
Chances are you’ve heard of or even used services like 23 & Me and Ancestry DNA.
There is an incredible demand for services like these; not only from consumers, but from the entire healthcare industry.
However, this is bigger than understanding which part of the world your ancestors are from.
This is about your future health.
Understanding, identifying and treating diseases before they become problems is the next frontier in the healthcare industry.
But that’s not all…
What if you could get medication and healthcare services that are specially designed for your unique genetics?
These new approaches are helping biotech companies develop therapies that were thought to have been incurable just a few years ago.
U.S. dominated the genetic testing market in 2017 with the “world genetic testing market” “projected to surpass USD 22 billion by 2024”.
But that’s just part of the story.
According to the “latest research study”, “the global big data analytics in healthcare market was valued at $16.87 billion in 2017, and is projected to reach $67.82 billion by 2025, growing at a CAGR of 19.1% from 2018 to 2025.”
This new frontier in the healthcare industry is wide-open, creating what could be one of the biggest opportunities for companies that provide genetic diagnostics and data analytics in healthcare.
PRED could be one of the most overlooked opportunities we have seen in this sector.
PRED “is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention.”
PRED “has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease’s onset and progression.”
PRED “uses this information as the cornerstone in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.”
Operationally, PRED’s combination of “proprietary gene-based companion diagnostics” and “data analytics” expertise gives the company a potentially massive competitive advantage in the industry.
PRED demonstrated in its most recent earnings filing the phenomenal growth rate of the company:
“Predictive Technology Group Reports Third Quarter Fiscal 2019 Financial Results”
“Nine-month revenue increased 217% to $30 million with $3.1 million in positive cash flow from operations”
Here are the CEO’s comments from this press release:
“I’m pleased to report our 10th consecutive quarter of sequential growth in revenue.”
“Third quarter fiscal 2019 revenue of $11.3 million was up 167% over the third quarter of fiscal 2018”.
Moreover, the company has been expanding in recent months and “has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories.”
PRED “announced the acquisitions of CLIA-approved Taueret Laboratories in March 2019 and Inception Dx in September 2018.”
In addition, PRED has been recruiting industry veterans to lead its expansion.
As part of its commitment to strong stewardship, just a few weeks ago PRED named a 25-year veteran of the women’s health field, as detailed in this company statement:
“Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, he will provide critical medical affairs support for the women’s health clinical franchise. Dr. Rabin has more than 25 years of experience in women’s healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.”
Not only that, but PRED has recently taken steps to put its biotech treatments through clinical trials, in a major step towards potential mass-market adoption.
PRED recently signed a “letter of intent with IQVIA” “to guide the regulatory strategy for its wholly owned subsidiary Predictive Biotech,” as detailed in this statement from the company:
“Specifically, IQVIA will guide Predictive Biotech in its U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application and subsequent clinical trial for osteoarthritis (OA) of the knee.”
“The Company expects to meet with the FDA during the third quarter of 2019 to discuss the submission of the IND with the objective of determining the safety and effectiveness of CoreCyte™ compared to a placebo control for [the] treatment of OA of the knee.”
“The Company will work with the FDA to determine if the FDA will accept the current safety data from over 75,000 patients previously treated with CoreCyte™.”
But why now? Why should you care?
As the company stated in it’s recent press release, “CoreCyte™ has the opportunity to address a significant unmet clinical need by providing an alternative to opioids, cortisone and/or hyaluronic injections for treating OA knee pain.”
In addition, the company recently announced that it “has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain.”
According to the National Institute on Drug Abuse, “every day, more than 130 people in the United States die after overdosing on opioids” while “roughly 21 to 29 percent of patients prescribed opioids for chronic pain misuse them.”
“The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse alone in the United States is $78.5 billion a year”.
This problem has created a new demand for non-opioid treatments for chronic pain and PRED could be one of the companies with the solution.
In addition to all of the above accomplishments, PRED has announced multiple breaking developments in the past few days.
Last week the company announced:
“Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration”
“Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally.”
This “global research collaboration” with Thermo Fisher Scientific is “focused on studying the genetic factors underlying infertility in women.”
“Worldwide, around 70 to 80 million couples currently experience infertility”.
PRED CEO Bradley Robinson stated the following regarding this breakthrough collaboration:
“Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions. Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next-generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.”
On Thursday, the company announced:
“Predictive Technology Group Announces the Presentation of New Genetic Findings in Endometriosis at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology”
“SALT LAKE CITY, June 20, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Kenneth Ward, M.D. will present new genetic findings in endometriosis at the 2019 European Society of Human Reproduction and Embryology (ESHRE) meeting on Monday, June 24 in Vienna, Austria.”
This presentation, which occurred today, could be another positive catalyst for PRED as more investors discover this opportunity.
But, that’s not all…
Just last month, PRED “completed the application and submitted the request to list Predictive on The NASDAQ Exchange.”
“The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards,” but it’s a sign of the company’s commitment to continued growth.
In the event that PRED can successfully accomplish this, they could position themselves in front of mainstream investors on Wall Street.
If all of the above wasn’t enough, PRED has a potentially remarkable chart setup and a history of experiencing massive gains.
PRED has seen a remarkable 2019, starting the year at 0.93 and rallying to a high of 6.91, upside of more than 643%.
Since this incredible rally, PRED has consolidated near its 20 day moving average (DMA) and could be positioned for another breakout higher.
PRED is an overlooked opportunity that has been growing at a remarkable pace and could be the solution for multiple high growth sectors within healthcare.
Make sure to do your own due diligence.
Up 13.6% !!! Should we all jump up and down!!!
Answer, no because a few % either way on a low volume stock is irrelevant. However I’m sure on every downtick you will jump up and down like a simpleton!!
This game has only started, may be a bit of shirt term gratification but the real game hasn’t even started tet
Thanks for the witty reply, intelligence suited to McDs . Congrats on reaching the peak of your career
McCarthy bought stock in old company at over a buck and was sold out at 33c!! Investment genius
Very small minded and novice attitude (to be expected from a small time guy) you don’t look at stocks like this over days! This is a slow burner. Last 3 months up 500%. Soooooo disappointing
You never owned the stock!! I know your history, you’re an old carry over shareholder who had stock at much higher levels and you were booted out of alpine (small account) at 209% loss. Now hanging around like a spoilt child who lost his toy ????
What’s the opposite of “timber” I’m not that smart. G is really smart, trading sdvice is “buy them high and sell them low. Genius
Up 500% from the low!! You sold it for 309% loss!!! I’m good thanks for the investment advice. Now back to work in McDonald’s now, your break is over
You’re a fool
You’re so dumb that you make a rock look like a Mensa member!
Do you also not realize that it’s a federal offence to be influencing anyone’s buying/selling decisions while being in possession of inside information.
The good thing about this is that when the authorities come knocking, they will have all your detailed.
Stupidity knows no bounds
Come on big mouth, spill!! Obviously one of the top auditing firms missed something that a smart guy like yourself knows. You’ve been here a long time and lost some money so your biased opinion would be really useful!
By all means do share! We are all ears. So far all we have heard from you is innuendo with zero substance. Spill it now so we all know. That’s what the board is about.
We know your game and your issues with the stock, getting booted by alpine,
The floor is yours MC.
The conference I agree won’t be monumental. I base my thoughts on a move north more on the stock drying up and I’m anticipating a nasdaq update very soon based on application timelines.
I’m not in this for short term moves as they only keep the masses happy. I want this on a big board so that it can be analyzed properly by people who understand the space and who arent spooked by pps swings.
Conference only started today and runs until Thursday. I wouldn’t expect to see anything until at least Tuesday as Dr Ward is presenting new findings on Monday
Mr MCCarthy, should we put out your address and phone number. Bought old stock at a buck plus and alpine sold your stock out at 30 c because you account isn’t. Big enough!! ???? big hitter here folks
It’s all fun and games but it’s nearly all over. Stock going up and when we hit nasdaq the big boys come to play.. sit and be happy, by year end Kong’s will be extremely happy with this.
I’d rather follow the smart guys (TMO) than a shister that shows up with zero substance